vtuking

US revokes emergency use of drugs touted by Trump vs. virus

President Donald Trump has long been fond of crafting his own version of the facts. But when he said “if we stop testing right now we’d have very few cases” of coronavirus, he may have written a new line of attack for critics who question his commitment to following the science.

His statement overlooks other important measures of the ongoing coronavirus threat, including hospitalizations and deaths.

Trump’s comment Monday was part of a broader administration effort to play down the pandemic, a push that public health experts and Democratic officials worry is sending a dangerous message to the American public as some parts of the country have seen a surge in cases in recent weeks.

U.S. regulators on Monday revoked emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19 amid growing evidence they don’t work and could cause serious side effects.

The Food and Drug Administration said the drugs hydroxychloroquine and chloroquine are unlikely to be effective in treating the coronavirus. Citing reports of heart complications, the FDA said the drugs’ unproven benefits “do not outweigh the known and potential risks.”

In a separate announcement, the FDA also warned doctors against prescribing the drugs in combination with redelivering, the lone drug currently shown to help patients with COVID-19. The FDA said the anti-malaria drugs can reduce the effectiveness of remdesivir, which FDA cleared for emergency use in May.

Hydroxychloroquine and chloroquine are frequently prescribed for lupus and rheumatoid arthritis and can cause heart rhythm problems, severely low blood pressure, and muscle or nerve damage. The agency reported Monday that it had received nearly 390 reports of complications with the drugs, including more than 100 involving serious heart problems. Such reports represent an incomplete snapshot of complications with the drugs because many side effects go unreported.

FDA’s move means that shipments of the drugs obtained by the federal government will no longer be distributed to state and local health authorities for use against the coronavirus. The decades-old drugs are still available for alternate FDA-approved uses, so U.S. doctors could still prescribe them for COVID-19 — a practice known as off-label prescribing.

Dr. Steven Nissen, a Cleveland Clinic researcher who has been a frequent FDA adviser, agreed with the decision and said he would not have granted emergency access in the first place.

“There has never been any high-quality evidence suggesting that hydroxychloroquine is effective” for treating or preventing coronavirus infection, he said, but there is evidence of serious side effects.

On Thursday, a National Institutes of Health panel of experts revised its recommendations to specifically recommend against the drug’s use except for informal studies, and “that, I’m sure, had to influence on the FDA,” Nissen said.

The actions by the FDA and NIH send a clear signal to health professionals against prescribing the drugs for coronavirus.

Trump aggressively pushed hydroxychloroquine beginning in the first weeks of the outbreak and stunned medical professionals when he revealed he had taken the drug preemptively against infection. After Trump’s repeated promotions, prescriptions for hydroxychloroquine soared, contributing to shortages.

No large, rigorous studies have found the drugs safe or effective for preventing or treating COVID-19. And a string of recent studies made clear they could do more harm than good.

Dr. Peter Lurie, a former FDA associate commissioner, and an Obama administration appointee, said the agency had tarnished its reputation by clearing the drugs based on scant evidence and under apparent political pressure.

“This is an agency that gains its credibility from the strength of its scientific pronouncements,” said Lurie, now president of the nonprofit Center for Science in the Public Interest. “The lesson of this whole tawdry episode is that it’s the old, painstaking ways of science that ultimately deliver safe and effective therapies.”

The only remaining drug with FDA authorization against COVID-19 is remdesivir, an intravenous medication from Gilead Sciences that has been shown to help severely ill, hospitalized patients recover faster.

Late Monday afternoon, the FDA announced it would update remdesivir’s prescribing label to warn against combining it with hydroxychloroquine or chloroquine. The agency said results from laboratory tests suggest the drugs interfere with remdesivir’s virus-fighting ability in human cells. Despite that risk, regulators said they have not yet seen the problem in patients.

The FDA granted emergency use for the anti-malaria drugs in late March at the same time the U.S. government accepted 30 million doses of hydroxychloroquine and chloroquine that had been donated by two foreign drug manufacturers. Millions of those doses were shipped to U.S. hospitals to treat patient who wasn’t enrolled in clinical trials.

But the FDA previously warned doctors that it had seen reports of dangerous side effects and heart problems reported to poison control centers and other health systems.

The agency said it revoked the authorization in consultation with the Biomedical Advanced Research and Development Authority, or BARDA, which had requested the emergency use.

BARDA’s former director said in April that he was removed from his job because he resisted political pressure from Trump appointees to allow widespread use of the malaria drugs. Rick Bright said he worked with FDA senior staff to limit the drugs’ authorization to patients hospitalized with COVID-19 and under professional supervision.

Among other issues, Bright objected to the fact that some of the doses imported were manufactured at facilities in India and Pakistan that had not been inspected by the FDA. Bright is seeking reinstatement to his position at BARDA after being transferred to the NIH.

The FDA says it sampled and tested the imported drugs to confirm they met the agency’s standards for safety and quality.

 

vtuking

26 Comments

  1. Reply

    Nice update

  2. Reply

    Nice update

  3. Reply

    Good to know

  4. Profile photo ofSIRMUSTY

    Reply

    stubborn president

  5. Reply

    Stubbornness

  6. Reply

    Hard to deal with Mr president

  7. Reply

    Good article

  8. Reply

    Ok

  9. Reply

    Om

  10. Reply

    The U.S. regulators on Monday revoked emergency authorization for malaria drugs promoted by President Donald Trump for treating COVID-19 amid growing evidence they don’t work and could cause serious side effects.

  11. Profile photo ofSommycruz

    Reply

    It’s fine

  12. Reply

    Jumboearn paid platform and news update

  13. Reply

    Good article

  14. Reply

    It’s fine

  15. Reply

    Good article

  16. Reply

    I thought the people for the virus drug trial volunteered

  17. Reply

    This is good to know

  18. Reply

    Good

  19. Reply

    Thanks for the update

  20. Reply

    Good to know

  21. Reply

    Interesting

  22. Reply

    Interesting

  23. Reply

    This is quite an interesting update
    Very informative too

  24. Reply

    Good

  25. Reply

    Nice article

  26. Reply

    Nice update

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these <abbr title="HyperText Markup Language">HTML</abbr> tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>